Acadia's pimavanserin fails in Phase III for Parkinson's-related psychosis
This article was originally published in Scrip
Executive Summary
Acadia Pharmaceuticals' lead candidate pimavanserin has failed to meet the primary endpoint in the first of two Phase III studies in Parkinson's disease psychosis (PDP).